Sign In
Buy TSHA
$5.55
-0.140 (-2.46%)
At Close: Jun 03, 2026
Taysha Gene Therapies: Shortened Timeline Increases The Potential
06:55am, Monday, 01'st Jun 2026
Taysha Gene Therapies is now a one-drug company, fully reliant on TSHA-102 for Rett syndrome after discontinuing its previous pipeline. I rate TSHA as a Buy, citing strong cash reserves, promising ear
Taysha Gene Therapies, Inc. (TSHA) Q1 2026 Earnings Call Transcript
04:11pm, Wednesday, 06'th May 2026
Taysha Gene Therapies, Inc. (TSHA) Q1 2026 Earnings Call Transcript
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
08:00am, Wednesday, 06'th May 2026
DALLAS, May 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-ba
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 01'st May 2026
DALLAS, May 01, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-ba
Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6
08:00am, Wednesday, 29'th Apr 2026
DALLAS, April 29, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-
In vitro data demonstrated self-complementary AAV9 (scAAV9) enabled ~30-fold higher MeCP2 protein expression compared to single-stranded AAV9 (ssAAV9), supporting the ability to effectively deliver TS
Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 6.9% After Analyst Upgrade
01:25am, Tuesday, 07'th Apr 2026
Shares of Taysha Gene Therapies, Inc. (NASDAQ: TSHA - Get Free Report) were up 6.9% during mid-day trading on Monday after Canaccord Genuity Group raised their price target on the stock from $14.00 to
Capricorn Fund Managers Ltd Makes New Investment in Taysha Gene Therapies, Inc. $TSHA
04:45am, Monday, 06'th Apr 2026
Capricorn Fund Managers Ltd purchased a new stake in Taysha Gene Therapies, Inc. (NASDAQ: TSHA) during the undefined quarter, according to the company in its most recent Form 13F filing with the Secur
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 03'rd Apr 2026
DALLAS, April 03, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-
Taysha Gene Therapies Q4 Earnings Call Highlights
02:34am, Saturday, 21'st Mar 2026
Taysha Gene Therapies (NASDAQ: TSHA) highlighted clinical, regulatory, and commercial progress for its lead Rett syndrome gene therapy program while also reporting higher operating expenses and a wide
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up Following Better-Than-Expected Earnings
01:14am, Saturday, 21'st Mar 2026
Taysha Gene Therapies, Inc. (NASDAQ: TSHA - Get Free Report) gapped up prior to trading on Thursday following a better than expected earnings announcement. The stock had previously closed at $4.45, bu
Taysha Gene Therapies, Inc. (TSHA) Q4 2025 Earnings Call Transcript
06:22pm, Thursday, 19'th Mar 2026
Taysha Gene Therapies, Inc. (TSHA) Q4 2025 Earnings Call Transcript
Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update
08:00am, Thursday, 19'th Mar 2026
Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2 2026
Ally Bridge Group NY LLC Acquires Shares of 1,898,112 Taysha Gene Therapies, Inc. $TSHA
03:31am, Sunday, 15'th Mar 2026
Ally Bridge Group NY LLC acquired a new position in shares of Taysha Gene Therapies, Inc. (NASDAQ: TSHA) during the undefined quarter, according to its most recent 13F filing with the SEC. The fund ac
Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19
08:00am, Thursday, 12'th Mar 2026
DALLAS, March 12, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-
